Study of combination therapy before surgery for ER+/HER2+ breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old who has been newly diagnosed with breast cancer.
- Your breast cancer must test positive for HER2 and have at least 10% ER (estrogen receptor) positive cells.
- The tumor must be larger than 2 cm or have spread to lymph nodes, but not to distant parts of the body (stage IV).
- You must have good organ function, including normal blood counts, liver and kidney tests, and a heart pump reading (LVEF) of 55% or higher.
- You cannot have had other cancer treatments or major surgery in the past 4 weeks, and must not be pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests whether adding the targeted drug pyrotinib to the standard HER2-targeted medicine trastuzumab after surgery can help lower the chance of early-stage HER2-positive breast cancer coming back.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.